BIOMAT Database Logo BIOMAT Database Logo

Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. 1986

D Bergqvist, and U S Burmark, and J Frisell, and T Hallböök, and B Lindblad, and B Risberg, and S Törngren, and G Wallin

In a randomized, prospective, double-blind multicentre trial, the effect of conventional low-dose heparin 5000 units twice daily, was compared with that of a low molecular weight heparin fragment (4000-5000) 5000 anti-factor Xa units once daily. Four hundred and thirty-two patients fulfilled the inclusion criteria and were analysed for development of deep vein thrombosis (125I-labelled fibrinogen test) and haemorrhagic complications. Thrombosis occurred in a 4.3 per cent of patients in the low-dose heparin group and in 6.4 per cent of patients in the heparin fragment group, a difference which is not significant. There was a significant delay in the onset of thrombosis in the heparin fragment group. Mortality did not differ between the groups, nor did peroperative blood loss or transfusion requirements or infectious complications. Haemorrhagic complications occurred significantly more often in the fragment group (11.6 per cent) than in the conventional heparin group (4.6 per cent). Patients in the heparin fragment group experienced local pain following the subcutaneous injection significantly less often.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006470 Hemorrhage Bleeding or escape of blood from a vessel. Bleeding,Hemorrhages
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

D Bergqvist, and U S Burmark, and J Frisell, and T Hallböök, and B Lindblad, and B Risberg, and S Törngren, and G Wallin
A prospective double-blind trial of a low molecular weight heparin once daily compared with a conventional low-dose heparin three times daily prevent pulmonary embolism and venous thrombosis in patients with hip fracture.
June 1990, The Journal of trauma,
D Bergqvist, and U S Burmark, and J Frisell, and T Hallböök, and B Lindblad, and B Risberg, and S Törngren, and G Wallin
A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture.
June 1989, The Journal of trauma,
D Bergqvist, and U S Burmark, and J Frisell, and T Hallböök, and B Lindblad, and B Risberg, and S Törngren, and G Wallin
[Bridging with low molecular weight heparin. Once daily or twice daily administration?].
March 2011, MMW Fortschritte der Medizin,
D Bergqvist, and U S Burmark, and J Frisell, and T Hallböök, and B Lindblad, and B Risberg, and S Törngren, and G Wallin
Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis.
February 1988, The British journal of surgery,
D Bergqvist, and U S Burmark, and J Frisell, and T Hallböök, and B Lindblad, and B Risberg, and S Törngren, and G Wallin
Low molecular weight heparin once versus twice for thromboprophylaxis following esophagectomy: a randomised, double-blind and placebo-controlled trial.
July 2015, Journal of thoracic disease,
D Bergqvist, and U S Burmark, and J Frisell, and T Hallböök, and B Lindblad, and B Risberg, and S Törngren, and G Wallin
Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial.
October 1997, The British journal of dermatology,
D Bergqvist, and U S Burmark, and J Frisell, and T Hallböök, and B Lindblad, and B Risberg, and S Törngren, and G Wallin
A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke.
October 1990, Seminars in thrombosis and hemostasis,
D Bergqvist, and U S Burmark, and J Frisell, and T Hallböök, and B Lindblad, and B Risberg, and S Törngren, and G Wallin
Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group.
May 1998, Thrombosis and haemostasis,
D Bergqvist, and U S Burmark, and J Frisell, and T Hallböök, and B Lindblad, and B Risberg, and S Törngren, and G Wallin
[Prevention of thrombosis in gynecology: double-blind comparison of low molecular weight heparin and unfractionated heparin].
September 1989, Geburtshilfe und Frauenheilkunde,
D Bergqvist, and U S Burmark, and J Frisell, and T Hallböök, and B Lindblad, and B Risberg, and S Törngren, and G Wallin
A multicentre, double-blind, randomized study to compare the safety and efficacy of once-daily ORG 10172 and twice-daily low-dose heparin in preventing deep-vein thrombosis in patients with acute ischaemic stroke.
November 1994, Age and ageing,
Copied contents to your clipboard!